Biotechnology - Anti-virals, Biotechnology

Filter

Current filters:

Anti-viralsBiotechnology

Popular Filters

1 to 25 of 160 results

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

23-07-2014

An anti-cancer drug developed by US biotech company Celgene Corp can re-activate dormant HIV which allows…

Aarhus UniversityAnti-viralsBiotechnologyCelgene Corp.DenmarkHIVHIV/AIDSIsodaxResearchromidepsin

Biotron’s BIT225 reverses HIV-induced impairment of the immune system

23-07-2014

Australian viral disease specialist Biotron presented data at the 20th International AIDS Conference,…

Anti-viralsAntiretroviral drugAustraliaBiotechnologyBiotronBIT225HIVHIV/AIDSImmune systemResearch

BioAlliance’s Sitavig debuts in USA; new patent granted

BioAlliance’s Sitavig debuts in USA; new patent granted

22-07-2014

French drug developer BioAlliance Pharma says that its US partner Innocutis Holdings has launched Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyHealth Medical PharmaHerpesInnocutis HoldingsLabial herpesMarkets & MarketingMedicineMicrobiologyPatentsSitavigUSA

Hepatitis C cured in co-infected HIV patients

Hepatitis C cured in co-infected HIV patients

21-07-2014

A multicenter team of researchers report that in a Phase III clinical trial, a combination drug therapy…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHepatitis CResearchRibavirinsofosbuvirSovaldiThe Johns Hopkins University School of MedicineUSA

Sinovac to provide hepatitis A vaccine in Beijing tender to 2016

Sinovac to provide hepatitis A vaccine in Beijing tender to 2016

21-07-2014

China-based Sinovac Biotech has been selected by the Beijing Health Bureau as the sole supplier of inactivated…

Anti-viralsBiotechnologyChinaHealthcareSinovac BiotechVaccination

The price of NOT curing hepatitis C - by Robert Zirkelbach

The price of NOT curing hepatitis C - by Robert Zirkelbach

20-07-2014

Over the past few months, there has been increased focus on the price of a new cure for hepatitis C,…

Anti-viralsBiotechnologyFinancialHealthcareHepatitis CHepatitis CLiver transplantsMedicineTradeUSA

Canada approves Pendopharm’s all-oral ribavirin treatment Ibavyr for hepatitis C

Canada approves Pendopharm’s all-oral ribavirin treatment Ibavyr for hepatitis C

16-07-2014

Quebec-based Pendopharm, a division of privately-held Canadian drugmaker Pharmascience, says the regulator…

Anti-viralsBiotechnologyCanadaIbavyrPendopharmPharmascienceRegulation

US Senators press for details on Gilead’s Sovaldi pricing

US Senators press for details on Gilead’s Sovaldi pricing

12-07-2014

Adding to previous criticism from the likes of the medical humanitarian organization Medecins Sans Frontieres…

Anti-viralsBiotechnologyGilead SciencesPoliticsPricingSovaldiUSA

Australia’s TGA clears the way for Gilead’s Sovaldi for hepatitis C

Australia’s TGA clears the way for Gilead’s Sovaldi for hepatitis C

08-07-2014

Australian health care regulator the Therapeutic Goods Administration (TGA) has approved the use of US…

Anti-viralsAustraliaBiotechnologyGilead SciencesRegulationSovaldi

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

27-06-2014

US biotech firm Gilead Sciences revealed this morning it has submitted a New Drug Application to Japan's…

Anti-viralsBiotechnologyGilead SciencesJapanRegulationSovaldi

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen

18-06-2014

US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

16-06-2014

In draft recommendations published today, UK health care watchdog the National Institute for Health and…

Anti-viralsBiotechnologyGilead SciencesPricingRegulationSovaldiUK

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

10-06-2014

US drugmaker Achillion has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for…

ACH-3422AchillionAnti-viralsBiotechnologyRegulationResearchsovaprevir

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

09-06-2014

There was good news for US antivirals major Gilead Sciences, when France’s health technology assessment…

Anti-viralsBiotechnologyFranceGilead SciencesPricingRegulationSovaldi

Biota Pharma plans restructuring following loss of BARDA contract

02-06-2014

USA-based Biota Pharmaceuticals has adopted a plan to restructure the company's operations following…

Anti-viralsBiota PharmaceuticalsBiotechnologyFinanciallaninamivirManagementUSA

Ventrus Biosciences boosted on merger plan with Assembly Pharma

19-05-2014

USA-based Ventrus Biosciences saw its shares leap 9.4% to $1.16 in pre-market trading, as it announced…

Anti-viralsAssembly BiosciencesAssembly PharmaceuticalsBiotechnologyMergers & AcquisitionsVentrus Biosciences

Janssen’s hepatitis C drug Olysio cleared in EU

16-05-2014

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson, says that its next…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonOlysioRegulation

Janssen submits sNDA for Olysio in combination with sofosbuvir

Janssen submits sNDA for Olysio in combination with sofosbuvir

08-05-2014

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson, has submitted…

Anti-viralsBiotechnologyGilead SciencesJanssenJohnson & JohnsonOlysioRegulationSovaldiUSA

Gilead’s Sovaldi shows “indication of added benefit for specific patients,” says IQWiG

Gilead’s Sovaldi shows “indication of added benefit for specific patients,” says IQWiG

03-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsBiotechnologyGermanyGilead SciencesPricingSovaldi

Professor Raymond Schinazi joins Board of reViral as Non-executive Director

Professor Raymond Schinazi joins Board of reViral as Non-executive Director

28-04-2014

UK-based antiviral drug discovery and development company reViral has announced the appointment of Professor…

Anti-viralsBiotechnologyBoardroomPharmaceuticalreViralUK

Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets

23-04-2014

US antivirals major Gilead Sciences posted first-quarter 2014 results after markets closed yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi

18-04-2014

NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment…

Anti-viralsBiotechnologyFinancialGilead SciencesHealthcareNorthern EuropeSovaldiUK

HIV market growth to be impacted by patent expiries

16-04-2014

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment…

Anti-viralsapricitabineAtriplaBiotechnologycensavudineelvucitabineGilead SciencesMarkets & MarketingPatentsResearchtenofovir alafenamideTruvadaViread

1 to 25 of 160 results

Back to top